March 2022 EIPM Director’s Memo

Dear Members of the Englander Institute,February was a busy month for many of our colleagues who participated in live and virtual events (see below). By sharing their expertise across a wide range of topics, these events help attract attention to the EIPM and raise our profile as we continue to grow and recruit new talent. Thank you for taking the time out of your busy schedules to participate in these panels and conferences. February 11th was International Day of Women and Girls in Science, and we used the occasion to celebrate and recognize on our social media channels some of the women who make the EIPM such a special place. Please follow us on TwitterFacebook, and Instagram for daily EIPM news and information. We have several new career opportunities, including a two-year Clinical Research Fellowship in Precision Medicine and a Laboratory Administrative Assistant. I encourage you to help us fill these positions by circulating them within your professional networks.Thank you for your hard work and continued dedication to our mission.Sincerely,Olivier Elemento, Ph.D.News Coverage & Awards Dr. Bishoy M. Faltas provided Expert Commentary submissions to UroToday: “Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma,” on February 7th; and “Early-Line Infigratinib for Patients with FGFR3-Altered Metastatic Urothelial Carcinoma,” on February 11thDr. Faltas also shared his “ASCO GU 2022: Next-Generation Sequencing: Discussing Results With Patients,” with UroToday on February 20th. Dr. Manish A. Shah discussed the “Potential clinical implications of the ongoing phase 3 GLOW trial in Claudin 18.2-positive, HER2-negative gastric/gastroesophageal junction adenocarcinoma,” with OncLive on February 1st. Our Molecular Aging Institute’s Clinical Director Dr. Pinkal Desai spoke with Oncology Times about research presented at the American Society of Hematology Annual Meeting, “COVID19 Survival With Acute Leukemia or Myelodysplastic Syndrome,” on February 20th. Dr. Lisa Newman spoke with patient Marina Hoffmann Norville about receiving genetic testing to learn about cancer risk and available treatments on the WCM’s Back to Health podcast on February 18th. Dr. Melissa B. Davis was interviewed for the article “Why Clinical Trials Need to Include More Black Women,” in Healthline on February 23rd. Dr. Peter Martin discussed a recent study of treatment patterns and outcomes of mantle cell lymphoma in the article “Real-World MCL Management Differs from Clinical Trials,” by Targeted Oncology on February 11th. 

EventsEIPM Member Dr. Rohit Chandwani spoke at the New York Genome Center’s Very Rare Cancer Consortium Disease Spotlight & Research Roundtable on Ampullary & Duodenal Cancer on February 3rd.

Clinical Director Dr. Cora N. Sternberg and expert panelists discussed locally advanced and metastatic urothelial carcinoma with a focus on frontline and maintenance therapy at an Around the Practice presentation hosted by CancerNetwork® in early February. Dr. Majd Al Assaad, a Research Fellow in Precision Medicine in the Department of Pathology and Laboratory Medicine, and a Member of the EIPM, presented an EIPM Conference lecture, “83-year-old patient with metastatic carcinoma of unknown primary: Unraveling molecular underpinnings to predict tissue of origin,” on February 3rd.  Dr. Ana Pombo of Humboldt Univ. of Berlin presented an EIPM Seminar, “Functional specialization of 3D Genome Structure in Cell Lineage Commitment,” on February 3rd.Dr. Melissa B. Davis delivered the Keynote address at the Morehouse Medical School’s 34th annual Curtis L. Parker Symposium on February 9th. Dr. Davis also spoke before the United Nation’s Division of Healthcare Management and Occupational Safety and Health about her @ICSBCS global approach to biological determinants of cancer disparities on February 14th. EIPM’s Director for Liquid Biopsy Research Dr. Pashtoon Kasi spoke at the 6th Annual Liquid Biopsy for Precision Oncology Summit on February 11-12th. Drs. Juan Miguel Mosquera (left) of the Pathology and Laboratory Medicine department, and the EIPM, and WCM’s Jones Nauseef, presented during the New York Genome Center’s “Polyethnic 1000 Consortium,” meeting on February 14th.I was honored to present, “Towards Organoid-Driven Cancer Precision Medicine,” at the University of Pittsburgh’s Precision Medicine Institute on February 16th. Dr. Andy J. Minn from the University of Pennsylvania and Dr. Silvia Formenti from the Meyer Cancer Center delivered Metastasis Working Group Seminar presentations on Feb 23rd.Dr. Iman Hajirasouliha of the EIPM and MCC presented a WCMC ICB Research in Progress Seminar, “Deep Learning in Embryology, Pathology, and Genomics,” on Feb. 25th.Dr. Shahin Rafii hosted a WCM Regenerative Medicine Seminar, “Sphingolipid and Inflammatory stress regulation of human hematopoietic stem cells,” presentation by Dr. Stephanie Chi Xie of the Princess Margaret Cancer Center in Toronto on February 22nd. Dr. Howard A. Fine presented a WCM Neurology department Grand Rounds lecture, “Human Cerebral Organoids: An Ex Vivo Model of Patient Specific Malignant Gliomas and Spontaneous Age-Related Human Gliomagenesis,” on February 23rd.Dr. Pinkal Desai participated in a WCM Myeloma Center virtual meeting on “Treating Hematologic Malignancies” on February 25th. Upcoming: In honor of March 3rds Triple Negative Breast Cancer Day, Dr. Melissa B. Davis will present a Karen’s Club lecture, “Triple Negative Breast Cancer: Information is Power, What Do We Need to Know.” Please also register today to hear Dr. Davis and our colleague Dr. Karla Ballman participating in the next Racial & Social Justice Book Club discussing the film “Picture a Scientist,” on March 29th. PublicationsClinical Director Dr. Cora N. Sternberg and colleagues published, “Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer,” in the New England Journal of Medicine on February 17th. Dr. Karsten Suhre co-authored “Qatar genome: Insights on genomics from the Middle East,” in Human Mutation on February 2nd. Dr. Lorenzo Galluzzi and colleagues published several articles this month including: “Immunogenic cell stress and death,” in Nature Immunology on February 10th; “Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents,” in Trends in Cancer on February 16th; and the commentary, “Immunostimulatory effects of radioimmunotherapy,” in BMJ’s Journal for ImmunoTherapy for Cancer on February 21st.Drs. Melissa B. Davis and Lisa Newman published, “Oncologic Anthropology: An Interdisciplinary Approach to Understanding the Association Between Genetically Defined African Ancestry and Susceptibility for Triple Negative Breast Cancer,” in Current Breast Cancer Reports on February 16th. Drs. André F. Rendeiro, Iman Hajirasouliha, myself, and a range of WCM investigators collaborated on “System-wide transcriptome damage and tissue identity loss in COVID-19 patients,” which appeared in Cell Reports Medicine on February 16th. EIPM’s Director for Liquid Biopsy Research Dr. Pashtoon Kasi published, “Beyond circulating tumor cell enumeration: cell-based liquid biopsy to assess protein biomarkers and cancer genomics,” in Frontiers in Pharmacologyon February 19th. “The EIPM has experienced strong growth in research outputs over the past five years with a strong focus on the life sciences,” Nature Index, February 28th.

# # #